Welcome to Atrial Fibrillation Association - US
Atrial Fibrillation Association - United States of America (AFA-US) is a non-profit organization which provides information, support and access to established, new or innovative treatments for Atrial Fibrillation (AFib).
Atrial Fibrillation (AFib) is the most common heart rhythm disorder (arrhythmia). It occurs when chaotic electrical activity develops in the upper chambers of the heart (the atria). As a result, the atria no longer beat in an organized, regular rhythm, so the patient's pulse is irregular and as a result, the pumping of the heart is less efficient. AFib affects approximately 2.5 million people in the United States and over five million in Western Europe.
AFA-US is affiliated to AFA International, a global charity based in the UK. Some materials on this site are shared with AFA-UK.
AFA-US is also affiliated to STARS-US, a US registered non-profit organization 501© (3) charity, committed to improving the quality of life for individuals and their families coping with Syncope conditions.
HRS 2013 - Denver
8 - 11 May 2013 - Denver, CO
Visit Trudie Lobban, CEO of AF-A and her colleagues at stand 319
What is AFib?
Heart Rhythm Week
Join hundreds of supporters across the UK and help raise awareness and promote better understanding of AF.
1 Mission 1 Million
The 1 Mission 1 Million (1M1M) initiative is going from strength to strength to support advancements in AFib-related stroke prevention. Sign the petition or join the discussion on Twitter #AFmission.
The aim is to get one million signatures from across the globe to raise awareness of AFib as a serious condition to health organizations all over the world.
Atrial Fibrillation Association (AFA) have launched the Global AF Charter at the World Heart Federation, World Congress of Cardiology Scientific Sessions in Dubai, to address the devastating affects of undiagnosed Atrial Fibrillation (AFib) and AFib-related strokes.
Download the Global AFib Charter
This consensus statement was written by leading experts in the area of stroke prevention in Atrial Fibrillation (AFib). The consensus development was spearheaded by the Atrial Fibrillation Optimal Treatment Task Force, led by the Alliance for Aging Research. The resulting statement provides a standardized approach to assessing moderate- to high-risk patients and determining who should be on an anticoagulant medication. Additionally, the document presents the leading stroke and bleeding risk tools all in one place--making them easy for health care professionals to access and compare.